Tony di Pietro
Director of Finance/CFO chez CANN GROUP LIMITED
Profil
Anthony Salvatore di Pietro is currently serving as the Secretary & Director at BARD1AG SA, a Member at the Australian Institute of Co. Directors, and a Member at the Governance Institute of Australia Ltd.
Previously, he held positions such as Chief Financial Officer, Secretary & Director at Sienna Cancer Diagnostics Ltd.
in 2020, Head-Investor Relations at Acrux Ltd.
from 2004 to 2014, and Chief Financial Officer & Joint Secretary at INOVIQ Ltd.
Additionally, he served as the Chief Financial Officer & Secretary at Genetic Technologies Ltd.
from 2022 to 2024.
Mr. di Pietro obtained his undergraduate degree from Swinburne University of Technology in 1997.
Postes actifs de Tony di Pietro
| Sociétés | Poste | Début |
|---|---|---|
| CANN GROUP LIMITED | Director of Finance/CFO | 08/04/2024 |
Governance Institute of Australia Ltd.
 Governance Institute of Australia Ltd. Miscellaneous Commercial ServicesCommercial Services Governance Institute of Australia Ltd. provides education, support, and networking opportunities for directors, Australian company secretaries, governance advisers, and risk managers. The private company is based in Sydney, Australia. Megan Motto has been the CEO of the company since 2019. | Corporate Officer/Principal | - |
Australian Institute of Co. Directors
 Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Corporate Officer/Principal | - |
BARD1AG SA
 BARD1AG SA Medical/Nursing ServicesHealth Services BARD1AG SA develops blood tests for the early detection of colorectal and lung cancer based on cancer-specific BARD1 isoforms. It offers screening and diagnosis services. The company was founded by Irmgard Irminger-Finger and Tony Walker in 2010 is headquartered in Geneva, Switzerland. | Director/Board Member | - |
Anciens postes connus de Tony di Pietro
| Sociétés | Poste | Fin |
|---|---|---|
| GENETIC TECHNOLOGIES LIMITED | Director of Finance/CFO | 25/03/2024 |
| INOVIQ LTD | Director of Finance/CFO | 02/11/2022 |
| ACRUX LIMITED | Director of Finance/CFO | 29/09/2014 |
| SIENNA CANCER DIAGNOSTICS LIMITED | Director of Finance/CFO | - |
Formation de Tony di Pietro
| Swinburne University of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| GENETIC TECHNOLOGIES LIMITED | Health Technology |
| ACRUX LIMITED | Health Technology |
| INOVIQ LTD | Health Services |
| CANN GROUP LIMITED | Process Industries |
| Entreprise privées | 4 |
|---|---|
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Commercial Services |
Sienna Cancer Diagnostics Ltd.
 Sienna Cancer Diagnostics Ltd. BiotechnologyHealth Technology Sienna Cancer Diagnostics Ltd. operates as a medical technology company. It delivers sensitive, novel, robust and test for early detection of cancer, assessment of cancer treatments and assistance in drug development. The company was founded in 2002 and is headquartered in Scoresby, Australia. | Health Technology |
Governance Institute of Australia Ltd.
Governance Institute of Australia Ltd. Miscellaneous Commercial ServicesCommercial Services Governance Institute of Australia Ltd. provides education, support, and networking opportunities for directors, Australian company secretaries, governance advisers, and risk managers. The private company is based in Sydney, Australia. Megan Motto has been the CEO of the company since 2019. | Commercial Services |
BARD1AG SA
BARD1AG SA Medical/Nursing ServicesHealth Services BARD1AG SA develops blood tests for the early detection of colorectal and lung cancer based on cancer-specific BARD1 isoforms. It offers screening and diagnosis services. The company was founded by Irmgard Irminger-Finger and Tony Walker in 2010 is headquartered in Geneva, Switzerland. | Health Services |
